Evidence map›Paper›PMID 41712129›Full record

ReviewStem cell reviews and reports2026

Unlocking Alveolar Regeneration: AT2 Stem Cells, Signaling Networks, and Therapeutic Frontiers.

Yihang Zhang, Yumei Zhou, Ji Wang, Qi Wang

Abstract readReview
In one paragraph

Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yihang ZhangThe Second Clinical Medical College, Henan University of Traditional Chinese Medicine, Zhengzhou, 450046, China.
Yumei ZhouNational Institute of TCM Constitution and Preventive Treatment of Disease, Wangqi Academy of Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. ymzhou666@163.com.
Ji WangNational Institute of TCM Constitution and Preventive Treatment of Disease, Wangqi Academy of Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. doctorwang2009@126.com.
Qi WangNational Institute of TCM Constitution and Preventive Treatment of Disease, Wangqi Academy of Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. wangqi710@126.com.

Funding

General program of National Natural Science Foundation of China 82204948
6 · The paper itself

Abstract

This review elucidates the pivotal role of alveolar type II epithelial cells (AT2) as key adult stem cells in lung homeostasis maintenance and post-injury repair, with molecular regulatory mechanisms. We synthesize current knowledge on AT2 self-renewal and differentiation into alveolar type I epithelial cells (AT1), and how their dysfunction drives refractory lung diseases such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. By evaluating findings from lineage tracing, single-cell transcriptomics, and three-dimensional organoid culture, this article outlines the cellular atlas of alveolar regeneration. This atlas encompasses not only AT2 cells and alveolar epithelial progenitors, but also auxiliary progenitor sources such as bronchioalveolar stem cells and lineage-negative epithelial progenitors. Notably, the review highlights the transitional plasticity stage—alveolar differentiation intermediate states—during AT2-to-AT1 differentiation. Mechanistically, the review delves into the intricate signaling networks governing AT2 cell fate, including key pathways such as Wnt/β-catenin, Hippo-YAP, Notch, and BMP. Crucially, it emphasizes that AT2 cell regenerative capacity relies on a multilayered quality control system involving epigenetic regulation, metabolic reprogramming, organelle homeostasis, and telomere maintenance. Furthermore, mesenchymal and immune cells within the alveolar stem cell niche engage in precise paracrine crosstalk with AT2 cells to collectively orchestrate regeneration. Finally, this review bridges fundamental biological discoveries with clinical prospects, illustrating how AT2 cells may serve as biomarkers for disease diagnosis, vehicles for gene-targeted therapy, and sources for cell replacement therapy. It outlooks novel treatments by modulating AT2 stem cell function—including small-molecule drugs, gene-editing nanoplatforms, and stem cell transplantation—heralding a transformative era in pulmonary regenerative medicine.

Indexed as

Alveolar Epithelial CellsPulmonary AlveoliRegenerationSignal TransductionStem CellsAnimalsCell DifferentiationHumansAlveolar regenerationAlveolar type II epithelial cellsCell quality controlTherapy

Identifiers

PMID41712129
PMCPMC13099710

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.